| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826593 | Current Opinion in Pharmacology | 2007 | 5 Pages |
Abstract
Glutathione (GSH) deficiency is associated with numerous pathological conditions. Administration of N-acetylcysteine (NAC), a cysteine prodrug, replenishes intracellular GSH levels. NAC, best known for its ability to counter acetaminophen toxicity, is a safe, well-tolerated antidote for cysteine/GSH deficiency. NAC has been used successfully to treat GSH deficiency in a wide range of infections, genetic defects and metabolic disorders, including HIV infection and COPD. Over two-thirds of 46 placebo-controlled clinical trials with orally administered NAC have indicated beneficial effects of NAC measured either as trial endpoints or as general measures of improvement in quality of life and well-being of the patients.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Kondala R Atkuri, John J Mantovani, Leonard A Herzenberg, Leonore A Herzenberg,